Skip to main content

Roivant Sciences Ltd. (ROIV) Stock Analysis

Range Bound setup

SellVALUE-TRAP 2/5Moderate Confidence

Healthcare · Biotechnology

Earnings in 1 day (2026-05-20). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $27.45: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum.

Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including brepocitinib (TYK2/JAK1), batoclimab/IMVT-1402 (anti-FcRn), and mosliciguat. Following its October 2024 sale of Dermavant, it has no commercialized products. As... Read more

$27.45+10.1% A.UpsideScore 4.4/10#137 of 157 Biotechnology
QualityF-score2 / 9FCF yield-1.64%
Stop $26.39Target $31.07(analyst − 13%)A.R:R 1.6:1
Analyst target$35.71+30.1%12 analysts
$31.07our TP
$27.45price
$35.71mean
$41

Sell if holding. Engine safety override at $27.45: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 4.4/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 1d<=7d. Suitability: moderate.

Val6.0Qual1.2Grw5.0Mom3.1Sent7.4Ins3.0Peer4.2Tech6.8Risk5.04.4OVERALL

Recent Developments — Roivant Sciences Ltd.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.2 < 4.0)
Value-trap signals (2/5): Material insider selling (13 sells, 0.03% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—
P/E (Fwd)-24.6
Mkt Cap$20.4B
EV/EBITDA-13.2
Profit Mgn0.0%
ROE-19.1%
Rev Growth-77.8%
Beta1.14
DividendNone
Rating analysts19

Quality Signals

Piotroski F2/9

Options Flow

P/C0.87neutral
IV70%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Moat
2.5
Current Ratio
5.0
Cash-burning: FCF -2512% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Obv
1.0
Volume
1.5
Macd
3.6
Ma Position
4.0
Rsi
5.5
Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
Earnings concerns: 2B/2MEarnings in 1 days
GatesMomentum 3.1<4.5EARNINGS PROXIMITY 1d<=7dA.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
56 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $27.06Resistance $29.80

Price Targets

$26
$31
A.Upside+13.2%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.2 < 4.0)
! Value-trap signals (2/5): Material insider selling (13 sells, 0.03% of cap), Negative free cash flow
! Momentum score 3.1/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-20 (1d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ROIV stock a buy right now?

Sell if holding. Engine safety override at $27.45: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10 and A.R:R 1.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $26.39. Score 4.4/10, moderate confidence.

What is the ROIV stock price target?

Take-profit target: $31.07 (+10.1% upside). Prior stop was $26.39. Stop-loss: $26.39.

What are the risks of investing in ROIV?

Quality below floor (1.2 < 4.0); Value-trap signals (2/5): Material insider selling (13 sells, 0.03% of cap), Negative free cash flow.

Is ROIV overvalued or undervalued?

Roivant Sciences Ltd. trades at a P/E of N/A (forward -24.6). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about ROIV?

19 analysts cover ROIV with a consensus score of 4.3/5. Average price target: $36.

What does Roivant Sciences Ltd. do?Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including...

Roivant Sciences is a clinical-stage biopharmaceutical company advancing therapies via 'Vant' subsidiaries, including brepocitinib (TYK2/JAK1), batoclimab/IMVT-1402 (anti-FcRn), and mosliciguat. Following its October 2024 sale of Dermavant, it has no commercialized products. As of March 31, 2025, it held $4.9B in cash to fund ongoing clinical programs.

Related stocks: INCY (Incyte Corporation) · ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · ONC (BeOne Medicines Ltd.) · CAI (Caris Life Sciences, Inc.)